The introduction of anti-vascular endothelial growth factor (VEGF) agents for treating exudative or neovascular age-related macular degeneration (nAMD) in 2006 and diabetic maculopathy (DME) in 2010 has dramatically improved the treatment outcomes of these previously blinding diseases [1]. Here, VEGFA is linked to wet macular degeneration.